XBP1通过调节氧化应激来调节衰老的心血管系统
Ji Zhang1,2, Yuanyuan Zhao2, Nianqiao Gong2
1Anhui Province Key Laboratory of Genitourinary Diseases, Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, Anhui Medical University, Hefei 230022, China.
Antioxidants (Basel, Switzerland)
|November 25, 2023
概括
X-box结合蛋白1 (XBP1) 调节衰老心脏病中的氧化应激. 了解XBP1通路为心血管和脏健康提供了新的策略.
科学领域:
- 分子生物学分子生物学
- 心血管科学 心血管科学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- X-box结合蛋白1 (XBP1) 是一种转录因子,在氧化应激中扮演着新兴的角色.
- 氧化压力有助于与年龄有关的心脏脏功能障碍.
- XBP1通路与心脏病的复杂网络有关.
研究的目的:
- 审查XBP1和氧化应激在心脏和脏疾病中的联系机制.
- 探索XBP1激活在衰老的心脏神经系统中的双重作用.
- 确定针对心血管和脏健康的XBP1的潜在治疗策略.
主要方法:
- 文献综述侧重于XBP1,氧化应激和心脏病.
- 对研究XBP1在线粒体功能,炎症和神经道驱动器中的作用的分析.
- 对与年龄有关的心脏病理生理学进行当前研究的综合.
主要成果:
- XBP1在调解细胞对氧化应激反应方面发挥着至关重要的作用.
- 在衰老过程中,XBP1通路的失调与心脏病相关.
- 根据背景,XBP1的激活可以产生保护性和有害的影响.
结论:
- XBP1是心脏神经系统中氧化应激的关键调节者.
- 准XBP1通路可能为与年龄相关的心脏脏疾病提供新的治疗途径.
- 对XBP1多方面的作用进行进一步的研究对于改善心血管和结局至关重要.
相关概念视频
Aging
56
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
56
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Antihypertensive Drugs: Action of β1 Blockers
453
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
453
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436


